The U.S. approval of Utility Therapeutics' Pivya (pivmecillinam) gives "health providers a powerful new tool to combat a common infection that is increasingly unresponsive to the existing suite of antimicrobial drugs," according to the New York Times.
The article highlighted the AMR Action Fund's role in investing in Utility and enabling the regulatory review, and it featured several quotes from CEO Henry Skinner, who said that while he was gratified by the F.D.A.'s approval, the long-term prognosis for new antimicrobial drugs remained grim. "There are definitely bright spots," he said. "But more people are dying today than ought to be because we are moving backward, and not delivering the physicians, drugs and diagnostics needed to address the crisis of antimicrobial resistance."
Read the full story here.
